Log In
Print
BCIQ
Print
Print this Print this
 

custirsen sodium (OGX-011, TV-1011)

  Manage Alerts
Collapse Summary General Information
Company OncoGenex Pharmaceuticals Inc.
DescriptionSecond-generation antisense inhibitor of serum clusterin mRNA
Molecular Target Clusterin mRNA
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$430.0M

$60.0M

$370.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today